Trust Signals
- Written by the FormBlends Medical Team, referencing primary trial data (Jastreboff et al., NEJM 2023) and FDA regulatory guidance.
- No vendor pays for placement on this page. Vendor criteria are based solely on documented COA transparency and manufacturing standards.
- All efficacy claims are graded by evidence tier. Speculative claims are labeled as such.
- Legal status section reflects U.S. federal law as of May 2026. Regulations change; verify with a licensed healthcare provider.
- This page is updated when new Phase 3 data or FDA actions materially change the risk-benefit picture.
Key Takeaways
- Retatrutide (LY3437943) is a GLP-1/GIP/glucagon triple agonist. In the Phase 2 NEJM trial (n = 338), the 12 mg weekly dose produced roughly 17.5% mean body weight loss at 24 weeks, the highest figure reported for any injectable agent at that timepoint.
- It is not FDA-approved as of May 2026. Buying it for human self-administration exists in a legally and medically uncontrolled grey zone.
- The single most important vendor filter is an independent, lot-specific HPLC plus mass-spec COA. No COA, or a vendor-generated COA, is disqualifying.
- Lyophilized peptide stored at 2 to 8 degrees Celsius degrades meaningfully faster once reconstituted. Improper storage is one of the commonest reasons real-world results diverge from trial data.
- Compounding pharmacies operating under physician oversight represent the highest-accountability sourcing path available today, but retatrutide's unapproved status creates legal uncertainty even there.
- What is retatrutide and why is it different from semaglutide and tirzepatide?
- What does the evidence actually show? (Evidence Ledger)
- Is it legal to buy retatrutide in the United States?
- What are the sourcing tiers and which is most accountable?
- How do I read a retatrutide COA and spot a fake?
- What most sourcing pages get wrong (the omitted risks)
- Why does storage matter so much? The chemistry behind the rule
- Honest head-to-head: retatrutide vs. approved GLP-1 options
- Dosing and reconstitution reference table
- FAQ
- Sources
What is retatrutide and why is it different from semaglutide and tirzepatide?
Retatrutide (development code LY3437943, Eli Lilly) is a single synthetic peptide molecule that simultaneously agonizes three receptors: glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR). Its molecular weight is approximately 4859 Da. Semaglutide targets only GLP-1R. Tirzepatide targets GLP-1R and GIPR. The addition of glucagon receptor activity is the structural differentiator.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Why does the glucagon receptor matter? Glucagon normally raises blood glucose and stimulates hepatic fat oxidation and thermogenesis. When glucagon agonism is combined with insulin-sensitizing GLP-1 activity, the net effect in trials is greater energy expenditure and hepatic fat reduction without the hyperglycemia that pure glucagon would cause. This triple mechanism is the pharmacological basis for the larger weight loss signals seen in Phase 2 data compared to dual agonists at matched time points. That said, the long-term safety profile of chronic glucagon agonism is not fully characterized. This is a mechanism that remains under investigation, not proven safe at scale.
What does the evidence actually show? (Evidence Ledger)
| Claim | Best Evidence Type | Key Source | Effect Direction | Confidence |
|---|---|---|---|---|
| Retatrutide causes substantial weight loss in adults with obesity | Phase 2 RCT, n=338, 24 to 48 weeks | Jastreboff et al., NEJM 2023 | Strong positive (up to ~17.5% at 24 wks, highest dose) | Moderate (Phase 2 only) |
| Glucagon agonism increases energy expenditure vs. GLP-1 alone | Preclinical and mechanistic studies | Multiple animal studies; Coskun et al. reviews | Positive (direction supported) | Low (mechanistic, not confirmed in humans at scale) |
| Retatrutide reduces hepatic fat content | Phase 2 RCT subgroup (MRI-PDFF) | Jastreboff et al., NEJM 2023 | Positive | Moderate |
| GI side effects (nausea, vomiting) are dose-dependent | Phase 2 RCT safety data | Jastreboff et al., NEJM 2023 | Positive (dose-response confirmed) | High |
| Heart rate increase with retatrutide | Phase 2 RCT | Jastreboff et al., NEJM 2023 | Modest increase observed (consistent with glucagon agonism) | Moderate |
| Long-term cardiovascular safety | No completed CVOT | Phase 3 TRIUMPH ongoing (as of May 2026) | Unknown | Very Low |
| Research-vendor peptide purity matches label claims | Independent third-party assays (not from trials) | No systematic published survey; anecdotal lab testing by hobbyist communities | Variable; failures documented informally | Very Low |
Is it legal to buy retatrutide in the United States?
Retatrutide is not FDA-approved for any indication as of May 2026. It is not a scheduled controlled substance under the DEA's lists, which means possession alone does not trigger criminal liability under federal law in the way a Schedule I substance would. However, selling it with any health claim, or selling it for human consumption, risks FDA enforcement under the Federal Food, Drug, and Cosmetic Act (misbranding and unapproved new drug provisions).
The "research chemical" or "not for human use" label that research vendors apply is a legal disclaimer designed to place the product outside FDA's food and drug framework. The FDA has the authority to challenge this framing and has done so with other peptides (notably BPC-157 and some GLP-1 compounds). Retatrutide has not been explicitly targeted by FDA warning letters as of this writing, but that status can change without notice.
For compounding pharmacies: a drug substance must appear on FDA's list of bulk drug substances eligible for compounding under Section 503A or 503B, or meet specific exemptions. Retatrutide does not currently appear on those lists, putting any compounded retatrutide in legally uncertain territory even from a licensed pharmacy. Patients considering any sourcing path should consult both a physician and, ideally, legal counsel.
What are the sourcing tiers and which is most accountable?
| Sourcing Tier | Oversight Level | COA Standard | Legal Status (US) | Typical Price Signal | Best Use Case |
|---|---|---|---|---|---|
| Eli Lilly clinical trial | FDA-IND, GMP manufacturing | Full pharmaceutical release testing | Fully legal (trial participant) | Free (trial sponsored) | Access Phase 3 TRIUMPH if eligible |
| Licensed compounding pharmacy (Rx required) | State pharmacy board, prescriber oversight | Variable; best pharmacies publish third-party COAs | Legally grey for unapproved compound | Higher than research vendors | Closest to clinical oversight outside trials |
| Established research-chemical supplier (COA-verified) | Self-regulated; no federal oversight | Third-party HPLC and MS, lot-specific (if reputable) | Grey; "not for human use" label | Mid-range | In vitro or animal research |
| Low-credibility online vendor (no traceable COA) | None | None or vendor-generated only | Grey to potentially illegal | Cheapest | Avoid for any use |
The clearest practical filter: if a supplier cannot give you a PDF COA with the name of an independent testing laboratory, a lot number matching the vial you ordered, an HPLC trace showing purity above 98%, and a mass-spec confirming molecular weight near 4859 Da, do not proceed.
How do I read a retatrutide COA and spot a fake?
What a real COA contains:
- Testing laboratory name that is not the vendor (search the lab independently to confirm it exists and offers peptide analysis services).
- Sample description including lot number. Cross-check this lot number against the label on the vial you received. Mismatched lot numbers mean the COA was not generated for your product.
- HPLC purity percentage with a chromatogram. For retatrutide, acceptable is above 98%. A purity line without a chromatogram is unverifiable.
- Mass spectrometry result confirming the molecular weight. Retatrutide's average molecular weight is approximately 4859 Da. A result significantly outside this range indicates the wrong compound or severe degradation.
- Residual solvent and/or endotoxin testing if the product is presented as injectable-grade.
- Date of analysis within the past 12 months for your batch.
Red flags indicating a fake or inadequate COA:
- COA is dated years before the product was supposedly manufactured.
- The "independent" lab has no web presence or verifiable contact information.
- Purity is listed as a round number like exactly 99.0% with no chromatogram.
- Vendor refuses to provide lot-specific documentation; only offers a generic product COA.
- Identity confirmed only by thin-layer chromatography (TLC) rather than HPLC plus MS. TLC cannot distinguish closely related peptide analogues.
What most sourcing pages get wrong (the omitted risks)
Almost every listicle comparing retatrutide vendors focuses on price per milligram and website aesthetics. Here is what those pages consistently omit:
1. Aggregation and impurity characterization. Peptides of retatrutide's size (39 amino acids, approximately 4859 Da) are vulnerable to aggregation during synthesis, lyophilization, and shipping. Aggregated peptide is not simply less potent. Aggregates can be immunogenic. No published data characterizes the immunogenicity risk of aggregated research-grade retatrutide in humans, which means the risk is unknown rather than zero.
2. Sequence accuracy is not the same as purity. A vendor can report 99% HPLC purity meaning 99% of the material elutes as one peak. If that peak corresponds to a truncated synthesis product at a similar molecular weight rather than full-sequence retatrutide, the HPLC number is technically correct but the material is wrong. Mass spectrometry is required to confirm sequence integrity, and even MS cannot fully confirm every possible synthesis error without fragment ion analysis.
3. Solvent and reconstitution compatibility. Research-grade retatrutide is typically supplied lyophilized and must be reconstituted. The wrong diluent (acidic vs. bacteriostatic water vs. saline) or vigorous shaking rather than gentle swirling can accelerate aggregation. Pharmaceutical-grade injectables include excipients specifically chosen to maintain stability in solution. Research vials do not.
4. Dose escalation is not optional. The Phase 2 trial used a structured dose-escalation schedule specifically because nausea and vomiting are dose-dependent and severe at full therapeutic doses. Research vendors and forum protocols that suggest starting at therapeutic doses without escalation are reproducing none of the safety conditions from the trial.
Why does storage matter so much? The chemistry behind the rule
Retatrutide is a peptide: a chain of amino acids linked by amide bonds. These bonds are susceptible to hydrolysis (cleavage by water molecules) and oxidation (particularly at methionine and tryptophan residues if present). Elevated temperature accelerates both processes by increasing molecular kinetic energy and the rate constants of these reactions. This is Arrhenius kinetics applied to peptide chemistry: a rough rule of thumb in pharmaceutical science is that reaction rates approximately double for every 10-degree Celsius increase in temperature, though the exact factor varies by compound.
Lyophilization (freeze-drying) removes water and dramatically slows hydrolysis, which is why lyophilized peptides stored cold retain potency far longer than solutions. Once you reconstitute with an aqueous diluent, hydrolysis resumes. Light exposure accelerates photooxidation of susceptible residues. This is why the rule "store lyophilized peptide at 2 to 8 degrees Celsius, away from light, reconstitute with sterile bacteriostatic water, use within weeks" exists. It is not arbitrary: it reflects the degradation chemistry of the molecule.
Practical consequences for buyers: a vendor that ships retatrutide without cold packs in summer, or stores product at room temperature in a warehouse, may be shipping partially degraded material regardless of what the original COA showed. The COA reflects the batch at time of testing, not at time of delivery.
Honest head-to-head: retatrutide vs. approved GLP-1 options
| Factor | Retatrutide (research source) | Tirzepatide (Mounjaro/Zepbound, Rx) | Semaglutide (Ozempic/Wegovy, Rx) |
|---|---|---|---|
| FDA approval | None | Yes (T2D and obesity) | Yes (T2D and obesity) |
| Weight loss evidence | Phase 2 only (~17.5% at 24 wks, 12 mg dose) | Phase 3 SURMOUNT: ~20-22% at 72 wks | Phase 3 STEP: ~15% at 68 wks |
| Cardiovascular outcome trial | None completed | SURPASS-CVOT: positive CV signal | SUSTAIN-6, SELECT: CV risk reduction confirmed |
| Manufacturing quality assurance | Variable, no regulatory oversight | GMP, full pharmaceutical QC | GMP, full pharmaceutical QC |
| Dosing precision | Requires manual reconstitution; error-prone | Pre-filled pen, fixed doses | Pre-filled pen, fixed doses |
| Medical monitoring | Typically none (self-administered) | Physician oversight required | Physician oversight required |
| Cost (out-of-pocket, US) | Lower per mg (no overhead), but hidden quality risk | High without insurance (~$1000+/mo) | High without insurance (~$900+/mo) |
| Retatrutide advantage | Potentially greater weight loss at longer durations (Phase 3 pending) | Proven Phase 3 data, CV safety data | Longest safety record of all three |
Honest conclusion: For a patient whose primary goal is medically supervised weight loss with the best available evidence and safety infrastructure, tirzepatide and semaglutide are ahead of research-grade retatrutide today, even if retatrutide's Phase 2 numbers look larger. Retatrutide's advantage, if it materializes in Phase 3, would be in degree of weight loss. It does not yet have an advantage in safety data, regulatory certainty, or access reliability.
Dosing and reconstitution reference table (research context only)
| Phase 2 Trial Dose Group | Starting Dose | Escalation Steps | Maximum Weekly Dose | Administration Route |
|---|---|---|---|---|
| Low | 1 mg weekly | Gradual escalation per protocol | 4 mg weekly | Subcutaneous injection |
| Mid | 1 mg weekly | Gradual escalation per protocol | 8 mg weekly | Subcutaneous injection |
| High | 2 mg weekly | Gradual escalation per protocol | 12 mg weekly | Subcutaneous injection |
Reconstitution math example (for research use): A 10 mg lyophilized vial reconstituted with 2 mL of bacteriostatic water yields a 5 mg/mL solution. A 1 mg research dose would require drawing 0.2 mL (200 microliters) with an insulin syringe. Verify your vial weight and diluent volume independently before any calculation. Errors in reconstitution volume are a direct source of dosing error.
FAQ
What is the best place to buy retatrutide peptides for research?
The best sources are licensed compounding pharmacies (for clinical use under a prescriber) or established research-chemical suppliers that publish third-party HPLC and mass-spec COAs with lot-specific results. No single vendor is universally best; COA transparency is the primary filter.
Is retatrutide legal to buy in the United States?
Retatrutide is not FDA-approved. It exists in a grey area: sale for research use is not explicitly prohibited under federal law, but it cannot be legally sold for human use without a prescription from a compounding pharmacy operating under valid medical oversight. Import for personal use carries additional risk.
What should a retatrutide COA include?
A credible COA should include: HPLC purity (ideally above 98%), mass spectrometry confirmation of the correct molecular weight (approximately 4859 Da for retatrutide), residual solvent testing, sterility or endotoxin data if intended for injection, and a lot number traceable to the batch you receive.
How do I verify a retatrutide vendor's COA is real?
Check that the COA names the independent testing lab (not the vendor's own lab), includes a lot number matching your product, shows a date within the past 12 months, and provides a HPLC chromatogram or mass-spec spectrum you can visually inspect. Call or email the listed lab to confirm the report if in doubt.
What purity percentage should retatrutide peptides be?
For research purposes, greater than 98% HPLC purity is the standard minimum. Products below 95% carry meaningful impurity burden. Impurities in GLP-1/GIP/glucagon triple agonists are not well-characterized for safety, so higher purity reduces unknown risk.
What is retatrutide and how is it different from tirzepatide?
Retatrutide (LY3437943) is a triple agonist targeting GLP-1, GIP, and glucagon receptors. Tirzepatide targets only GLP-1 and GIP. The added glucagon agonism in retatrutide is hypothesized to increase energy expenditure and hepatic fat reduction, contributing to the larger weight loss seen in Eli Lilly's Phase 2 trial.
How should retatrutide peptide vials be stored?
Lyophilized (freeze-dried) retatrutide should be stored at 2 to 8 degrees Celsius and shielded from light. Once reconstituted, peptide solutions degrade more rapidly and should be used within a few weeks under refrigeration. Freeze-thaw cycles accelerate aggregation and should be avoided.
Has retatrutide completed Phase 3 clinical trials?
As of May 2026, retatrutide has completed Phase 2 trials (published in NEJM, 2023) showing substantial weight loss in adults with obesity. Phase 3 trials (TRIUMPH program) are ongoing. It has not received FDA approval as of this writing.
What were the weight loss results in the retatrutide Phase 2 trial?
In the Phase 2 trial published in the New England Journal of Medicine (Jastreboff et al., 2023), participants receiving the highest retatrutide dose (12 mg weekly) achieved a mean body weight reduction of approximately 17.5% at 24 weeks, with the trial running to 48 weeks.
What are the main side effects of retatrutide?
The most common side effects reported in the Phase 2 trial were gastrointestinal: nausea, vomiting, diarrhea, and constipation. These were generally dose-dependent and most frequent during dose escalation. Serious adverse events were reported in a minority of participants. Heart rate increases were also observed, consistent with glucagon receptor agonism.
Can retatrutide be compounded legally?
Compounding of a drug substance requires it to be on FDA's 503A or 503B approved bulk substance list, or to meet specific exemptions. Retatrutide is not currently FDA-approved, meaning licensed compounding of it for human use operates in a legally uncertain space. Consult a healthcare provider and legal advisor before pursuing compounded retatrutide.
How do research-chemical retatrutide prices compare to pharmaceutical alternatives?
Research-chemical retatrutide is significantly cheaper per milligram than prescription GLP-1 agonists like semaglutide or tirzepatide when accessed through pharmacy channels. However, the lower price reflects the absence of pharmaceutical-grade manufacturing controls, sterility testing, and regulatory oversight, all of which carry real safety value.
Sources
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine. 2023;389(6):514-526.
- U.S. Food and Drug Administration. Compounding: Bulk Drug Substances Under Section 503A and 503B. FDA.gov. Accessed May 2026.
- U.S. Food and Drug Administration. Federal Food, Drug, and Cosmetic Act (FD&C Act). Chapter V: Drugs and Devices. FDA.gov.
- Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon-, GIP-, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism. 2022;36(12):1783-1800.
- Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021;385(6):503-515.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387(3):205-216.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384(11):989-1002.
- United States Pharmacopeia (USP). General Chapter 1059: Excipients for Biopharmaceuticals. USP-NF. (Stability and excipient guidance for peptide formulations.)
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research. 2010;27(4):544-575. (Foundational reference on peptide aggregation and degradation mechanisms.)